Chronic myelogenous leukemia

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Retrieved on: 
Thursday, March 21, 2024
ACT, Gene silencing, Metabolism, Conference, Immunotherapy, CD25, CD98, Compound, RNA interference, Bone marrow, Poster, NK, Chronic myelogenous leukemia, Pharmaceutical industry

The data reveals a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation.

Key Points: 
  • The data reveals a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation.
  • These preclinical data demonstrate the potential of INTASYL Compound PH-905 to improve Adoptive Cell Therapy (ACT) by targeting and silencing Cbl-b.
  • This may result in a more effective cell therapy for hematological malignancies.
  • INTASYL compound PH-905 may be used to improve the anti-tumor response of NK cells to provide a more effective cell therapy for cancer treatment.

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Retrieved on: 
Monday, December 4, 2023
Food, Syndrome, Chronic myelogenous leukemia, Acute lymphoblastic leukemia, Tmax, FDA, Plasma, Imatinib, Blood, NDA, Therapy, PDGFR, Parkinson's disease, Pancreatic serous cystadenoma, Patient, Mastocytosis

BOSTON and ATLANTA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro and to review the data establishing doses of IkT-001Pro bioequivalent to 400 mg and 600 mg imatinib mesylate. The Company expects to provide an update following the meeting.

Key Points: 
  • The Company expects to provide an update following the meeting.
  • “We are pleased that the FDA has granted a pre-NDA meeting to discuss the parameters for approval of IkT-001Pro,” stated Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics.
  • Across all doses, there were only mild adverse events observed, including just two adverse events for IkT-001Pro at the highest dose comparison.
  • Pharmacokinetic profiles for imatinib delivered by IkT-001Pro and imatinib mesylate were similar at equivalent doses.

Global Myeloproliferative Disorders Drugs Research Report 2023: Market is Expected to Surpass $10.5 Bn in 2027 - Focus on JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Pharmaceutical, Health, Incidence, Imago, Bristol Myers Squibb, Nilotinib, Pancreatic serous cystadenoma, Primary myelofibrosis, FDA, Ageing, Radiation exposure, Merk, Growth, Bone marrow, Polycythemia, DSM-IV codes, Chronic myelogenous leukemia, Foundation for the National Institutes of Health, Pharmaceutical industry

The "Myeloproliferative Disorders Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myeloproliferative Disorders Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • In the rapidly advancing pharmaceutical landscape, the significance of myeloproliferative disorder drugs is more pronounced than ever.
  • Driving the surge in the market for these drugs is the escalating incidence of myeloproliferative disorders.
  • The countries covered in the myeloproliferative disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month

Retrieved on: 
Monday, September 18, 2023
Human, Acute lymphoblastic leukemia, Senior, ALL, Mantle cell lymphoma, Myelodysplastic syndrome, Malignancy, Bone marrow, Research, Hodgkin lymphoma, Doctor of Philosophy, National Comprehensive Cancer Network, NCCN, MDS, Congress, CAR, AML, Patient, SAN, Hematology, MM, Memorial Sloan Kettering Cancer Center, MCL, Acute leukemia, Conference, Acute myeloid leukemia, Chronic myelogenous leukemia, Multiple myeloma, Vaccine, Rare-earth element, Primary myelofibrosis, MD

SAN FRANCISCO, Sept. 18, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the first time since 2019. The meeting features insights from world-renowned experts on providing optimal, evidence-based treatment for various blood cancers, plus best practices for protecting vulnerable populations in a changing healthcare landscape.

Key Points: 
  • The meeting features insights from world-renowned experts on providing optimal, evidence-based treatment for various blood cancers, plus best practices for protecting vulnerable populations in a changing healthcare landscape.
  • NCCN 2023 Annual Congress: Hematologic Malignancies is taking place September 22-23, 2023.
  • "This will help us all to achieve the best possible outcomes for people with blood cancer in a rapidly evolving landscape."
  • Save the dates: the NCCN 2024 Annual Conference will be happening in Orlando, FL April 5 - 7, 2024.

Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month

Retrieved on: 
Monday, September 18, 2023
Human, Acute lymphoblastic leukemia, Senior, ALL, Mantle cell lymphoma, Myelodysplastic syndrome, Malignancy, Bone marrow, Research, Hodgkin lymphoma, Doctor of Philosophy, National Comprehensive Cancer Network, NCCN, Hilton San Francisco Union Square, MDS, Congress, CAR, AML, Patient, SAN, Hematology, MM, Memorial Sloan Kettering Cancer Center, MCL, Acute leukemia, Conference, Acute myeloid leukemia, Chronic myelogenous leukemia, Multiple myeloma, Vaccine, Primary myelofibrosis, MD

SAN FRANCISCO, Sept. 18, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the first time since 2019. The meeting features insights from world-renowned experts on providing optimal, evidence-based treatment for various blood cancers, plus best practices for protecting vulnerable populations in a changing healthcare landscape.

Key Points: 
  • The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.
  • "We designed a comprehensive program for the entire hematology and oncology team—taking into account the latest advances, conversations, and controversies in blood cancer treatment today," said congress Chair Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center.
  • "This will help us all to achieve the best possible outcomes for people with blood cancer in a rapidly evolving landscape."
  • Save the dates: the NCCN 2024 Annual Conference will be happening in Orlando, FL April 5 - 7, 2024.

Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa

Retrieved on: 
Friday, September 15, 2023
Infection, Patent, Travel, College, Parasitism, Orbital Technologies Commercial Space Station, Drug discovery, Clinical trial, Enzyme, Malaria, African, Research, Fever, Open Philanthropy (organization), Chronic myelogenous leukemia, Pharmacotherapy, Low, Drug resistance, Death, Protein, Rupture, Philip B. Low, Novartis, Developed country, Patient, Philanthropy, Blood, Cancer, Chloroquine, Growth, College of Science (Northeastern University), Disease, Vaccine, Pharmaceutical industry, Chemistry, Purdue University

While studying how malaria propagates in human blood, Low and his research team discovered that the cancer drug therapy imatinib is effective in the treatment of drug-resistant malaria.

Key Points: 
  • While studying how malaria propagates in human blood, Low and his research team discovered that the cancer drug therapy imatinib is effective in the treatment of drug-resistant malaria.
  • Trials in Southeast Asia showed that imatinib, when combined with the customary malaria therapy, clears all malaria parasites from 90% of patients within 48 hours and 100% of patients within three days .
  • Open Philanthropy has awarded Low $600,000 for a larger clinical trial in Southeast Asia to validate his previous trials.
  • His work also receives support from the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery .

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Retrieved on: 
Tuesday, August 8, 2023
Reflex, Laboratory, Workflow, CML, EMR, BCR, Mutation, BCR-ABL, Cell, Electronic health record, Point mutation, Patient, Cell division, LIS, Diagnosis, Health, ABL1, Economics, Chronic myelogenous leukemia, Medical device, HAVEN

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.

Key Points: 
  • NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.
  • For more information on this new panel please visit us at https://tinyurl.com/QBCR-ABL1 .
  • The following features make this product the most advanced BCR-ABL panel on the market, besting competition in terms of robust coverage, workflow ease, accuracy, and cost:
    1.
  • Precipio’s HemeScreen BCR-ABL 2.0 assay is the only panel on the market that provides quantitative coverage of four clinically relevant2,3 breakpoints – p.190, p.210, p.203 and p.230.

Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, General Health, Pharmaceutical, Health, Safety, Refractory, Science, Translational research, Update, Myeloproliferative neoplasm, Myelodysplastic syndrome, ALK, Center for International Blood and Marrow Transplant Research, Activin and inhibin, DLBCL, European Hematology Association, Research, Polycythemia vera, Combination therapy, S110, Chronic lymphocytic leukemia, Abstract, Combination, Chronic myelogenous leukemia, Cytokine release syndrome, ALL, CRS, Relapse, OPTIC, Lymphoma, MOST, Cancer, Diffuse large B-cell lymphoma, Neoplasm, ALK2, Abstract (summary), CML, PV, ASCO, BET, American Society of Clinical Oncology, EHA, Annual general meeting, Anemia, Society, Pharmaceutical industry, Communications satellite, Allotransplantation, Hydroxycarbamide, Primary myelofibrosis, Patient

ET)

Key Points: 
  • ET)
    Phase 1b, Open-Label Study of Add-On Therapy with CK0804 in Participants with Myelofibrosis, with Suboptimal Response to Ruxolitinib (Abstract #TPS7087.
  • ET)1
    A Phase 1/2 Study of Retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) Combination Therapy in Patients (Pts) with Advanced Solid Tumors (Abstract #2599.
  • ET)
    Abstracts are available on the EHA2023 Congress platform and accessible for on-demand viewing until August 15, 2023.
  • ET)5
    For full session details and data presentation listings, please see the ASCO ( https://conferences.asco.org ) and EHA2023 ( https://ehaweb.org/congress ) online programs.

Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

Retrieved on: 
Monday, May 22, 2023
Minimal residual disease, MRD, Patient, CML, Chronic myelogenous leukemia, History, Medical imaging, HAVEN

While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician.

Key Points: 
  • While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician.
  • Changes in isoform expression may happen over time during the course of treatment.
  • The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab.
  • “We, and our customers, continue to see the benefits of using the HemeScreen BCR-ABL1 panel both in lab operations efficiencies and results such as these that enable doctors to make more informed care decisions.”

Dana Farber Cancer Institute’s Jimmy Fund Celebrates 75 years of Progress and Impact on May 22

Retrieved on: 
Monday, May 22, 2023
Research, General Health, Philanthropy, Pharmaceutical, Oncology, Hospitals, Fund Raising, Foundation, Clinical Trials, Science, Other Philanthropy, Health, Other Science, Truth or Consequences, Imatinib, Oxygen, Worcester Red Sox, Food and Drug Administration, Dana–Farber Cancer Institute, Wilms' tumor, Patient, Brookline Avenue, Showcase, The Jimmy Fund, Faculty, Charitable organization, Nobel Prize, Acute lymphoblastic leukemia, Multiple myeloma, Fear, Nobel Prize in Physiology or Medicine, FDA, Pan-Mass Challenge, PD-L1, Volunteering, Boston Braves, ALL, Boston Red Sox, Cancer, Charity Navigator, History, CAR, Jimmy, Lymphoma, Partnership, Clinical trial, Fenway Park, Chronic myelogenous leukemia, BCEC, Greater Boston, Herb Chambers, City, Physician, Atlanta Braves, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medicine, Iron, Pharmaceutical industry, Nursing, Television, Auction, MD, Physiology

Special anniversary events will continue throughout the summer to celebrate 75 years of the Jimmy Fund and support of cancer care and research at the #1 ranked cancer center in New England.

Key Points: 
  • Special anniversary events will continue throughout the summer to celebrate 75 years of the Jimmy Fund and support of cancer care and research at the #1 ranked cancer center in New England.
  • Not only did he get his wish, but more than $200,000 was collected and the Jimmy Fund was born.
  • Activities for the Jimmy Fund’s 75th (#JimmyFund75) anniversary include:
    Proclamation – Boston Mayor Michelle Wu will issue a City of Boston Proclamation, announcing May 22 as Jimmy Fund Day.
  • Light Boston Blue for the Jimmy Fund – Many of Boston’s most popular landmarks and structures will light up in the Jimmy Fund’s signature blue to celebrate the Jimmy Fund on the evening of May 22.